Mitochondrial uncouplers with an extraordinary dynamic range
- PMID: 17608618
- PMCID: PMC2267406
- DOI: 10.1042/BJ20070606
Mitochondrial uncouplers with an extraordinary dynamic range
Abstract
We have discovered that some weak uncouplers (typified by butylated hydroxytoluene) have a dynamic range of more than 10(6) in vitro: the concentration giving measurable uncoupling is less than one millionth of the concentration causing full uncoupling. They achieve this through a high-affinity interaction with the mitochondrial adenine nucleotide translocase that causes significant but limited uncoupling at extremely low uncoupler concentrations, together with more conventional uncoupling at much higher concentrations. Uncoupling at the translocase is not by a conventional weak acid/anion cycling mechanism since it is also caused by substituted triphenylphosphonium molecules, which are not anionic and cannot protonate. Covalent attachment of the uncoupler to a mitochondrially targeted hydrophobic cation sensitizes it to membrane potential, giving a small additional effect. The wide dynamic range of these uncouplers in isolated mitochondria and intact cells reveals a novel allosteric activation of proton transport through the adenine nucleotide translocase and provides a promising starting point for designing safer uncouplers for obesity therapy.
Figures
Similar articles
-
Mitochondrial uncoupling caused by a wide variety of protonophores is differently sensitive to carboxyatractyloside in rat heart and liver mitochondria.Biochim Biophys Acta Bioenerg. 2024 Nov 1;1865(4):149506. doi: 10.1016/j.bbabio.2024.149506. Epub 2024 Aug 20. Biochim Biophys Acta Bioenerg. 2024. PMID: 39168228
-
Alkyl esters of 7-hydroxycoumarin-3-carboxylic acid as potent tissue-specific uncouplers of oxidative phosphorylation: Involvement of ATP/ADP translocase in mitochondrial uncoupling.Arch Biochem Biophys. 2022 Oct 15;728:109366. doi: 10.1016/j.abb.2022.109366. Epub 2022 Jul 22. Arch Biochem Biophys. 2022. PMID: 35878680
-
The ATP/ADP-antiporter is involved in the uncoupling effect of fatty acids on mitochondria.Eur J Biochem. 1989 Jul 1;182(3):585-92. doi: 10.1111/j.1432-1033.1989.tb14867.x. Eur J Biochem. 1989. PMID: 2546761
-
Uncouplers of oxidative phosphorylation.Environ Health Perspect. 1990 Jul;87:213-8. doi: 10.1289/ehp.9087213. Environ Health Perspect. 1990. PMID: 2176586 Free PMC article. Review.
-
Mitochondrial ATP-Pi exchange complex and the site of uncoupling of oxidative phosphorylation.Fed Proc. 1975 Jul;34(8):1699-706. Fed Proc. 1975. PMID: 1093889 Review.
Cited by
-
Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane.Mol Metab. 2013 Nov 28;3(2):114-23. doi: 10.1016/j.molmet.2013.11.005. eCollection 2014 Apr. Mol Metab. 2013. PMID: 24634817 Free PMC article.
-
Adaptive translational pausing is a hallmark of the cellular response to severe environmental stress.Mol Cell. 2021 Oct 21;81(20):4191-4208.e8. doi: 10.1016/j.molcel.2021.09.029. Mol Cell. 2021. PMID: 34686314 Free PMC article.
-
Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing.EMBO Mol Med. 2014 May;6(5):624-39. doi: 10.1002/emmm.201303016. EMBO Mol Med. 2014. PMID: 24648500 Free PMC article.
-
Targeting energy expenditure via fuel switching and beyond.Diabetologia. 2011 Feb;54(2):237-44. doi: 10.1007/s00125-010-1932-4. Epub 2010 Oct 17. Diabetologia. 2011. PMID: 20953861
-
A novel kinetic assay of mitochondrial ATP-ADP exchange rate mediated by the ANT.Biophys J. 2009 Mar 18;96(6):2490-504. doi: 10.1016/j.bpj.2008.12.3915. Biophys J. 2009. PMID: 19289073 Free PMC article.
References
-
- Harper J. A., Dickinson K., Brand M. D. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes. Rev. 2001;2:255–265. - PubMed
-
- Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397. - PubMed
-
- Halford J. C. Obesity drugs in clinical development. Curr. Opin. Investig. Drugs. 2006;7:312–318. - PubMed
-
- Cutting W. C., Mehrtens H. G., Tainter M. L. Actions and uses of dinitrophenol. JAMA, J. Am. Med. Assoc. 1933;101:193–195.
-
- Tainter M. L., Stockton A. B., Cutting W. C. Dinitrophenol in the treatment of obesity: final report. JAMA, J. Am. Med. Assoc. 1935;105:332–336.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
